Johnson & Johnson (J&J) is expanding its pharmaceutical manufacturing capabilities in the United States with a 55 billion USD investment, including two new plants in North Carolina and Pennsylvania. This strategic move is expected to create hundreds of local jobs, according to state officials. J&J, however, has not yet disclosed the total capital investment or the specific locations for each new facility.
This expansion follows J&J's recent investments totaling billions of USD into its US manufacturing system over the past 10 months. Last year, the corporation broke ground on a biopharmaceutical manufacturing plant spanning approximately 46,500 square meters in Wilson, North Carolina. Concurrently, J&J signed a 2 billion USD agreement with Fujifilm Biotechnologies to lease manufacturing space at the Holly Springs, North Carolina facility for 10 years.
Beyond these two projects, J&J plans another multi-billion USD manufacturing facility in Wilson, marking its third investment in North Carolina within one year. The state government will support this project through its Industrial Development Fund and a 12 million USD budget to expand the training center at Wilson Community College. This particular plant is projected to create up to 500 jobs. In Pennsylvania, the corporation intends to build a new-generation cell therapy manufacturing facility, aligning with the trend of other life science companies, such as Eurofins and GSK, expanding their operations in the state.
J&J's investment aligns with a recent agreement between the corporation and President Donald Trump's administration. This agreement provides J&J with exemptions from certain import tariffs, allowing the company to reduce drug prices for American consumers. Furthermore, under this agreement, J&J joined the direct drug sales platform TrumpRx.gov, enabling people to purchase drugs at discounted prices comparable to those in many other countries.
J&J has indicated it will announce more investment plans in the US in the coming period. This trend is not exclusive to J&J; many other large pharmaceutical corporations are also increasing investment to strengthen their presence in the US market amid rising tariff risks. In June last year, AstraZeneca announced plans to invest 50 billion USD in US production and research and development, while AbbVie committed to spending 100 billion USD in this sector over the next 10 years.
The Dan (according to *Supply Chain Dive*)
